The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.
 
Yi-Tsung Lu
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Patents, Royalties, Other Intellectual Property - US Patent No. 10823736 Method of assessing disease condition of cancer
Travel, Accommodations, Expenses - Seagen
 
Melissa Plets
No Relationships to Disclose
 
Gareth Morrison
Employment - Private Health Management
 
Alexander T. Cunha
Employment - GenVivo
Stock and Other Ownership Interests - Amgen; Illumina
 
Steven Y. Cen
No Relationships to Disclose
 
Suhn K. Rhie
No Relationships to Disclose
 
Kimberly Siegmund
No Relationships to Disclose
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Olympus; pacific edge; Photocure; QED Therapeutics
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Photocure
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Joshua J Meeks
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; incyte; Janssen; Merck; Nucleix; Urogen pharma
Consulting or Advisory Role - AstraZeneca; Ferring; Merck
Research Funding - Epizyme; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme
 
Seth P. Lerner
Stock and Other Ownership Interests - C2i genomics
Honoraria - Annenberg Center for Health Sciences at Eisenhower (ACHS); Clinical Care Options; Grand Rounds in Urology; Ology Medical Education; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; C2i Genomics; FerGene; Ferring; Merck Sharp & Dohme; Pfizer/EMD Serono; Roche/Genentech; Urogen pharma; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Urogen pharma; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
David James McConkey
Honoraria - BioClin Therapeutics; H3 Biomedicine; Janssen Oncology
Research Funding - AstraZeneca; BioClin Therapeutics
Travel, Accommodations, Expenses - BioClin Therapeutics; H3 Biomedicine
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Ian M Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Amir Goldkorn
Research Funding - Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.